patient with hypercortisolemic syndrome without evidence of adrenal disease. Cushing read Bauer's report and recommended that he reexamine the pituitary gland. The specimen was found to have a basophilic pituitary tumor. 6, 63 At about the same time, Cushing published his landmark work on basophilic adenomas of the pituitary body 24 and the clinical syndrome of hypercortisolemia, which soon came to be known as "Cushing syndrome." 12 Despite the mounting evidence linking hypercortisolemia and pituitary tumors, 64 microadenomas were difficult to diagnose, and transsphenoidal surgery was not popular at this time. Thus, the condition was usually considered to be a metabolic disorder caused by increased adrenal gland hormone secretion. 2 Additional doubts regarding the link between hypercortisolemia and pituitary tumors developed after the authors of an autopsy study reported in 1935 that 7% of normal (nonhypercortisolemic) pituitary specimens contained a basophil adenoma. 22 A similar syndrome was found in a patient with a tumor of the thymus, which added to the confusion among the medical establishment. 53 An antipituitary camp, led by Kepler, 51 maintained the belief that the only cause of Cushing syndrome was adrenal disease. In fact, it was not until 1950, when Bauer 6 published his paper, "The so-called Cushing's syndrome," that a real distinction was made between hypercortisolism caused by adrenal disease and that caused by a pituitary tumor. Bauer wrote that "Cushing's disease, therefore, is the association of the known clinical syndrome with 'pituitary basophilism.' Hence it is this association not the clinical syndrome that should bear the eponym 'Cushing's disease,'" but the distinction was not widely accepted until 1972. 9 Because of the controversy and limited understanding of pituitary physiology and disease, adrenalectomy was most often the primary treatment of Cushing syndrome at the time Nelson and colleagues initially described the syndrome of ACTH hypersecretion. Pituitary surgery was usually reserved for cases involving visual loss and was performed almost exclusively with craniotomy. At that time, it was known that Cushing syndrome was attributable to excess adrenal steroids in the blood, 47 that this excess was unhealthy, and that adrenalectomy improved the clinical syndrome and extended the life expectancy of patients with this disease. Although there are scattered reports of cases of Cushing disease that were successfully treated with pituitary surgery (the earliest in 1933 by Dr. Naffziger 58 ), pituitary surgery undertaken to treat endocrinological disorders was not truly accepted until after transsphenoidal microsurgery was reintroduced to the neurosurgical community by Jules Hardy in 1971, 31 and Tyrrell et al. 90 and Salassa et al. 84 reported the cure of hypercortisolemia with the removal of microadenomas in their respective surgical series of 1978.
History of Nelson Syndrome
Until the 1950s, only rather primitive mechanisms were available for evaluating adrenal cortical function. Despite the fact that Dr. Thomas Addison 1 had described the syndrome of adrenal insufficiency in 1855, little was known about the hormones involved. While he was a research fellow, and later as a postdoctoral fellow at the University of Utah in the 1940s, Nelson and his colleagues working in Leo Samuels's laboratory endeavored to discover and quantify the adrenal steroids in human blood and serum. 89 The specific steroid to be measured remained unknown until 1953. 83 In 1950, Nelson and Samuels (Fig. 2 ) published a paper in which they described the process for isolating a steroid hormone from the blood of dogs. 74 The availability of the "Nelson-Samuels" method allowed the accelerated pursuit of the physiology of adrenocortical secretions, 10, 11, 33, 75 including the ability to measure corticosteroids in human blood. 76 Nelson was drafted into military service in 1952 and continued his research at the Naval Medical Research Institute in Bethesda. He continued to study adrenal physiology, and in 1955 he, along with his colleague David Hume, reported a method they had developed to determine the concentration of ACTH in human serum. 71 This test was a bioassay in which they used hypophysectomized dogs. It was rather crude by modern standards, but significantly elevated levels of ACTH could be determined. Nelson then used this assay while serving as a house officer and research fellow at the Peter Bent Brigham Hospital in Boston to study the physiology in Cushing syndrome, especially in cases in which no pituitary or adrenal tumor could be found. This was the only assay available to measure ACTH, and it was used in the first reported case of hyperpigmentation, elevated serum ACTH level, and pituitary tumor as well as visual loss in a patient who had undergone adrenalectomy for Cushing syndrome. It was this postadrenalectomy syndrome that later became known as Nelson syndrome (the pituitary tumor was often called a Nelson tumor).
In 1958, Nelson and colleagues 72 reported in the New England Journal of Medicine (Fig. 3 ) the case of their 33-year-old woman, "C.R." She had initially presented in 1954 with a 1-year history of nervousness, weakness, leg cramps, amenorrhea, acne, hirsutism, deepened voice, abdominal striae, polydipsia, and polyuria. On physical examination, she was observed to be obese, with a moon face, acne, mild hirsutism, and multiple ecchymoses and abdominal striae. She was hypertensive, her visual fields were normal, and her pituitary fossa size was "at the upper limits of normal" on a skull x-ray film. Laboratory studies revealed that she had glycosuria and hyperglycemia as well as an elevated level of 17-hydroxycorticosteroids in her urine. One month after her initial presentation, the patient underwent bilateral adrenalectomy. Her adrenal glands were normal in weight, but hyperplasia was demonstrated histologically. Postoperatively, she was placed on a daily regimen of 50 mg of cortisone. After 2 months, her symptoms had resolved, her endocrinological levels were normal, and she began to menstruate normally. Two years later, she complained of menorrhagia and cutaneous pigmentation, but no other abnormalities were found, and her serum glucose level remained normal. In 1957, 3 years after her initial presentation, the patient began to suffer renewed amenorrhea and progressive loss of vision in her left eye. On examination, her skin was found to be deeply pigmented (Fig. 4) , and she had a nearly complete bitemporal hemianopsia. Examination of laboratory studies showed that the level of 17-hydroxycorticosteroids was normal, but the level of ACTH exceeded 200 mU/100 ml (normal levels were undetectable using the Nelson-Hume method). A radiographic workup, including skull radiographs, laminagrams, and a fractional air study, now demonstrated expansion of the sella turcica with destruction of the dorsum sellae and the presence of a suprasellar tumor. Radiotherapy was initiated, but after 24 treatments hemorrhage into the tumor suddenly occurred. Because of the apoplexy, the patient was taken to the operating room where she underwent urgent decompression via craniotomy. A soft, hemorrhagic tumor was resected without complication, and she recovered well. Her vision improved, and her ACTH level became undetectable. She underwent monitoring for an additional 18 weeks. During this time, her cutaneous pigmentation subsided (Fig. 4) and her ACTH remained low, similar to that of other patients with hypoadrenocorticism. 11 In discussing this case, Nelson first debated the possibility of two causes of Cushing syndrome: one of adrenal and one of pituitary origin. He stated that a pituitary tumor should elevate the serum ACTH level but admitted that his "methods for the determination of ACTH in plasma are generally not sensitive enough" to determine moderately increased levels. He also surmised that the patient might have had an ACTH-secreting pituitary tumor and that "the removal of the adrenal glands may have acted as a stimulus to the pituitary gland, with growth of the tumor and increased secretion of ACTH resulting." Finally, he concluded that "development of a pituitary tumor is a possible sequela of bilateral adrenalectomy for Cushing's syndrome."
Because many adrenalectomies were being performed, it became increasingly evident that, in a certain population of patients, adrenalectomy caused the clinical syndrome of Nelson was able to report the abnormally high levels of this hormone after adrenalectomy. 77 By 1960, he had identified 10 patients with this "post-adrenalectomy" syndrome. 73 In this second paper on the syndrome (Fig. 5) , Nelson made three notable observations. First, he discovered the suppressibility of ACTH secretion in patients with pituitary tumors after they were given hydrocortisone therapy. Second, he described a patient who suffered from Cushing syndrome and was found to have an elevated ACTH level but no evidence of a pituitary tumor. This patient underwent a partial adrenalectomy, which led to a remission of the Cushing syndrome, but later suffered recurrence of the Cushing syndrome, an increased ACTH level, and a sellar tumor but no hyperpigmentation. Nelson himself remarked, "It has not been possible with the present technic [sic] to detect normal circulating levels of plasma-ACTH, and therefore a slight elevation of ACTH above 'normal' would presumably not be detected by the assay procedure used." Six years later he reported the elevation of ACTH in a patient with Cushing syndrome and a pituitary tumor before any treatment, foreshadowing the importance of this test in the determination of a pituitary source of Cushing syndrome. 77 Because of their low sensitivity, serum ACTH assays could not be used routinely to differentiate pituitarydependent from primary hypercortisolemia until much later. Last, Nelson concluded that in patients presenting with postadrenalectomy pituitary tumors, the evidence "strongly suggests either that the tumor was present prior to bilateral adrenalectomy, or that there was some abnormal stimulus to the pituitary gland which may have acted to produce the pituitary adenoma in these particular cases." This again highlights the uncertainty of the causes of Cushing syndrome into the 1960s.
Given the confusion over the cause, the typical treatment paradigm for Cushing syndrome of the 1950s and into the 1970s-the use of adrenalectomy-was targeted at the final common pathway, regardless of the cause of the hypercortisolemia. 28 Irradiation of the sella was sometimes performed, 65 and hypophysectomy was generally considered if there were overt signs of a sellar tumor, usually in association with a patient's loss of vision. Given the fact that there was still a great deal of controversy surrounding the cause of Cushing syndrome, there was no standard of care.
Nelson and Cushing Syndromes in the Modern Era
The development of Nelson syndrome after adrenalectomy for Cushing syndrome has been reported in between 8 and 47% of cases. 4, 15, 16, 19, 28, 30, 45, [48] [49] [50] 62, 65, 68, 80, 87, 95 These numbers vary depending on the extent of adrenalectomy, the causes of the hypercortisolemia in the treated patients, and the year the surgery was performed. As endocrinological, radiological/imaging, and neurosurgical advances were made in the understanding of and ability to diagnose the causes of Cushing syndrome and the modes of therapy, management of both Cushing and Nelson syndromes moved into the modern era.
The advances in endocrinology led to a better ability to diagnose Cushing disease and differentiate its various causes. The first development, as described above, was the ability to measure corticosteroid 76 and ACTH 71 levels in human blood samples. In part because of the observations made by Nelson in 1960, the low-and high-dose dexamethasone suppression tests became available to differentiate adrenaland pituitary-dependent hypercortisolemia. Liddle 55 reported that the abnormally elevated levels of urinary corticosteroids were suppressed in all patients with a known pituitary tumor by high doses of dexamethasone (2 mg every 6 hours) but not with low doses (0.5 mg every 6 hours). Individuals with a known adrenal tumor were completely resistant to high and low doses of the drug. This was the first reliable test to differentiate among the causes of Cushing syndrome. Although this test offered improved ability for differentiation because it was somewhat specific, it was not very sensitive, as many patients tested equivocally. 54, 93 Therefore, again following the lead of Nelson, the assay for the determination of ACTH in plasma was refined. With the production of specific antibodies, 31 a radioimmunoassay could be performed. In 1964, Yalow et al. 97 reported the results of an assay for ACTH that required less than 0.2 ml of serum and had a sensitivity as low as 0.06 mU/100 ml, approximately 100-fold more sensitive than Nelson's bioassay. 77 This allowed the detection of mildly elevated ACTH levels that could be caused by a pituitary microadenoma. With the advent of stimulation testing with corticotropin-releasing factor, the ability to distinguish the different causes of Cushing syndrome became even more widely available. 67 Several advances in radiography and neuroimaging also led to a change in the differential diagnosis of Cushing syndrome. A patient with Cushing syndrome or hyperpigmentation after adrenalectomy was typically screened with radiographs of the skull only. 92 In 1973, the computed tomography scanner was introduced to clinical medicine 42 and was soon used to obtain images of the brain and sella turcica. 3, 69, 78 This was soon followed by the development of MR imaging in the late 1970s. 23, 27, 38, 43, 66 The computed tomography and MR imaging findings correlated with surgical findings in 42 and 52% of cases of ACTH-secreting microadenomas, respectively. 17 High field strength MR imagers and dynamic imaging techniques have improved the sensitivity in recent years. 13 Last, the invasive endovascular technique of inferior petrosal sinus sampling was developed, 21 yielding very high sensitivity and specificity in cases of pituitary-dependent Cushing disease. 5, 59 The last advances to consider in the recent developments in management of Cushing disease are the contributions of neurosurgeons. Pituitary surgery was initially attempted in 1893 by Caton and Paul 18 in a patient with acromegaly. It soon became apparent to the neurosurgical community, however, that pituitary surgery was a morbid endeavor and therefore its use was largely abandoned, except in the most extreme cases, which were treated with transcranial operations. 60 The earliest reported successful pituitary surgery for microadenoma-related Cushing disease was conducted in 1933 (but not published until 1944), 58 yet most patients with Cushing syndrome and a pituitary tumor underwent sellar radiotherapy and adrenalectomy; the adrenalectomy treated the hypercortisolemia and the radiotherapy successfully controlled the growth of most of these tumors. 14, 46 With improvements in antibiotic therapy and intraoperative technology (including instrumentation, operative microscopy and microsurgery, and fluoroscopy), transsphenoidal pituitary surgery slowly gained acceptance, largely because of the work of Jules Hardy. 36 As pituitary surgery became more widely accepted, it was used successfully to treat Cushing disease but was still not considered the standard of care into the 1980s. For instance, there was debate over the effectiveness of prophylactic sellar irradiation in the prevention of Nelson syndrome. 45, 57, 65 In 1980, Nelson wrote in an editorial, "in those patients who fail to be cured adequately by the transsphenoidal approach, irradiation should be considered." 70 These advancements associated with improved management of Cushing syndrome also apply to the diagnosis and treatment of Nelson syndrome. Currently, measurement of ACTH is a reliable and routine laboratory investigation that is widely available. Even minor elevations in ACTH levels can be identified after adrenalectomy, and further investigations can be performed. Serial imaging after treatment for Cushing disease is now routine. Initially, the sella was imaged only with skull radiography, 92 but current MR imaging systems can detect small-size tumors. 52 Similarly, the surgical treatment of Nelson tumors has evolved. The earliest report of pituitary surgery for Nelson syndrome was published by Espinoza et al. 29 in 1973, who performed surgery in three patients via a transsphenoidal approach and were able to normalize the ACTH in two and reduce the level in the third patient postoperatively; no more than immediate results were reported.
Although the authors of early series found only limited success after transsphenoidal pituitary surgery for Nelson syndrome (27% success), 94 the authors of later reports showed somewhat better outcomes (success rate range 46-80%). 32, 50, 95 As with other tumors of the pituitary, residual or recurrent tumors can be treated with stereotactic radiosurgery. ity and can lead to biochemical cure in 74 to 78% of cases. 20, 86 Reoperation should be considered in cases of accessible residual or recurrent tumor, including total hypophysectomy. 8, 61 For unresectable disease (that is, cavernous sinus invasion), radiation can be delivered via conventional means or using conformal techniques. 85 Adrenalectomy should be considered only after therapy directed at the pituitary gland has failed. After adrenalectomy, patients must be carefully observed with serial MR imaging and laboratory investigations. The use of prophylactic sellar irradiation in the cases of persistent hypercortisolemia and without the demonstration of pituitary adenoma is controversial. 34 
Conclusions
Thus, all the pieces came together to bring Cushing syndrome into the contemporary era. The different causes of this syndrome can be diagnosed with great accuracy, and microsurgical treatment directed at the pituitary is safe and effective in experienced hands. 20, 39, 82, 86 The disease in few patients is refractory to multimodal therapy directed at the sella for pituitary-dependent Cushing disease, which includes surgery, conventional radiotherapy, stereotactic radiosurgery, 81, 85 and medical therapy. 37 Thus, once it became apparent that pituitary tumors could cause hypercortisolemia and tests became available to diagnose the cause, the number of patients undergoing adrenalectomy in the modern era decreased, and even fewer are developing Nelson syndrome. In light of these considerations, we believe that Nelson syndrome should be reevaluated to determine the roles of surgery, radiotherapy, and radiosurgery in the modern era.
